IonQ, Rigetti, and D-Wave Are Surging Again. Is Quantum Computing Finally Real?

Quantum computing stocks IonQ, D-Wave, and Rigetti have surged 50% or more since late March after $2 billion in federal funding was announced for the sector, but the article argues the technology is still a decade or more from fault-tolerant commercial viability. Valuations are extremely stretched, with price-to-sales ratios of 95.7x for IonQ, 645.4x for D-Wave, and 632.2x for Rigetti, leaving the group highly vulnerable to any shift in sentiment. The piece is broadly bearish on near-term upside and warns these speculative names could be hit hard in a market correction.

Analysis

The market is confusing subsidy validation with commercialization validation. Federal capital lowers financing risk and extends runway, but it does not solve the core bottleneck: error correction and useful workload density. That means the immediate beneficiaries are not the pure-play names so much as the ecosystem suppliers and adjacent incumbents that can monetize R&D while the sector remains in pre-revenue mode; the pure plays are effectively trading as long-duration call options on a breakthrough that may still be years away.

Second-order, the government funding can actually make the trade more fragile by concentrating ownership and attention into a small basket of momentum names. When a stock is priced primarily on narrative, any disappointment in additional awards, technical milestones, or follow-on financing can trigger multiple compression before fundamentals matter. The setup looks especially vulnerable to a broad growth-factor drawdown because these names have no earnings cushion and their valuations leave almost no room for execution slippage.

The contrarian read is that the move may still be under-owned on the positive side for the industrial-defense complex rather than over-owned in the pure plays. Quantum is becoming a national-security procurement story first and a commercial computing story second, which suggests longer-dated beneficiaries could include semiconductor, cryogenic, test-and-measurement, and security software vendors tied to the buildout. But for the direct stocks, the asymmetry is poor: upside requires a multi-year technical inflection, while downside can happen immediately if risk appetite normalizes.

Catalyst-wise, the next 1-3 months matter more for sentiment than science. Watch for a fade in post-announcement momentum, any delayed grant disbursement, or management guidance that implicitly acknowledges the long commercialization runway. If the broader market enters a correction, these names should underperform high-beta software by a wide margin because they are now priced like venture outcomes inside public-market wrappers.

Key Decisions for Investors

• Short IONQ / QBTS on strength over the next 1-3 weeks, using rally days into volume as entry; risk/reward favors a 15-25% downside retrace if momentum cracks, while upside is capped by already-stretched multiples.
• Pair trade: long INTC or NVDA vs short QBTS or IONQ for a 3-6 month horizon; the long leg has real cash-flow support and benefits from quantum-adjacent capex without binary technology risk, while the short leg is exposed to multiple compression.
• Buy medium-dated put spreads on QBTS rather than outright shorts if borrow is tight; target a 2:1 or better payoff around any sector-wide risk-off event or post-grant disappointment.
• If wanting quantum exposure, prefer ecosystem names with diversified demand streams over the pure plays; avoid initiating new long positions in IONQ/QBTS until either revenue inflects meaningfully or the sector de-rates by at least 30-40%.
• Set a tactical alert for any broad Nasdaq pullback of 5%+; use it as a trigger to add to shorts in the most sentiment-sensitive quantum names, since they should be among the first factor casualties.